RÉSUMÉ
It is unknown whether physiological ageing also goes along with electromechanical asynchrony of contraction. Aim of the study was to evaluate synchrony of contraction in older people with ("non-healthy") or without ("healthy") evidence for structural cardiac disease. In 547 persons (age 76.7+/-5.5 years, 306 male, 241 female) recruited from a population-based cohort of the ActiFE-Ulm study including a random sample of people >/=65 years old living in the region of Ulm, Germany, various PW- and TDI-Doppler based markers for asynchrony were obtained by echocardiography. Within a subgroup of 84 healthy subjects, at most minimal systolic and diastolic asynchrony was found. Concerning systolic asynchrony, similar observations were made within the non-healthy subgroup. However, extent of diastolic left ventricular intraventricular asynchrony and also - by tendency - diastolic interventricular asynchrony was increased in comparison to the healthy subgroup. To conclude, no evidence that physiological ageing might go along with relevant left or right ventricular systolic or diastolic electromechanical asynchrony was found in our study. Furthermore, our population-based data support the results from other clinical studies with rather selected cohorts that structural heart diseases might go along with increased diastolic asynchrony.
Sujet(s)
Dysfonction ventriculaire gauche/physiopathologie , Dysfonction ventriculaire droite/physiopathologie , Fonction ventriculaire gauche , Fonction ventriculaire droite , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Vieillissement , Études transversales , Diastole , Échocardiographie-doppler , Couplage excitation-contraction , Femelle , Allemagne/épidémiologie , Humains , Mâle , Facteurs de risque , Systole , Dysfonction ventriculaire gauche/imagerie diagnostique , Dysfonction ventriculaire gauche/épidémiologie , Dysfonction ventriculaire droite/imagerie diagnostique , Dysfonction ventriculaire droite/épidémiologieRÉSUMÉ
Necrotising fasciitis is a rare infection with a high mortality rate. Clinical manifestation may be influenced by an underlying disease state. We report a case of a 70-year-old man with an anaplastic large-cell lymphoma who presented with inconclusive signs of necrotising fasciitis following a neutropenic phase after chemotherapy. Surgical exploration did not reveal the typical macroscopic features of necrotising fasciitis. Microbiological investigations revealed Escherichia coli. The lack of massive tissue inflammation, probably due to the neutropenia in our patient, has not been described by other authors. Diagnostic uncertainties owing to masked or uncharacteristic signs in immune compromised patients may lead to a delayed surgical debridement, of which clinicians should be aware.
Sujet(s)
Infections à Escherichia coli , Fasciite nécrosante , Lymphomes/complications , Neutropénie , Sujet âgé , Escherichia coli , Humains , MâleRÉSUMÉ
Maintenance of postural balance requires an active sensorimotor control system. Current data are limited and sometimes conflicting regarding the influence of the proprioceptive, visual, and vestibular afferent systems on posture control in children. This study investigated the development of sensory organization according to each sensory component in relation to age and sex. A total of 140 children (70 males, 70 females; mean age 10y [SD 4y]; age range 3y 5mo-16y 2mo) and 20 adults (10 males, 10 females; mean age 30y 6mo [SD 8y 4mo]; age range 17y 2mo-49y 1mo) were examined using the Sensory Organization Test. Participants were tested in three visual conditions (eyes open, blindfolded, and sway-referenced visual enclosure) while standing on either a fixed or a sway-referenced force platform. Mean equilibrium scores for the six balance conditions showed rapid increases and maturation ceiling levels for age-related development of the sensorimotor control system. Proprioceptive function seemed to mature at 3 to 4 years of age. Visual and vestibular afferent systems reached adult level at 15 to 16 years of age, revealing differences between young males and females. Characterizing balance impairments can contribute to the diagnostic evaluation of neuromotor disorders.
Sujet(s)
Perception auditive/physiologie , Posture/physiologie , Proprioception/physiologie , Labyrinthe vestibulaire/physiologie , Perception visuelle/physiologie , Adolescent , Facteurs âges , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Facteurs sexuelsRÉSUMÉ
Age and cardio-vascular pathologies in hemodialysis patients confront us with the increasing difficulties in finding vascular access. This implies the necessity to keep in place central venous catheters (CVC) and find alternative puncturing sites. CVC malfunction in dialysis is frequently encountered (87% of cases). A variety of salvage procedures are described in the literature amongst them the "stripping" and re-canalization methods. Stripping allows withdraw fibrin strands around the CVC with a success rate of 75 to 90% and a rather low complication rate, although this may not be well documented. Re-vascularization techniques allow the placement of a CVC even across a thrombosed vessel. Success rate here is 100% in a limited series of patients. In addition to the classical access sites, like internal jugular and subclavian vein exist, alternative sites such as the external jugular, femoral or even translumbar vein.
Sujet(s)
Cathétérisme veineux central , Dialyse rénale , Cathétérisme/méthodes , Humains , Degré de perméabilité vasculaire , Veines , Thrombose veineuseRÉSUMÉ
Purpose: Recently, a Southwest Oncology Group study (SWOG 8507) demonstrated increased efficacy for a bacillus Calmette-Guerin (BCG) maintenance (mtce) program (3 weekly treatments at 3 months, 6 months, and every 6 months thereafter for 3 years) following 6 weekly instillations with BCG as compared to no mtce ("6+3" protocol). The remarkable results from the mtce arm were unfortunately accompanied by grade 3 or 4 toxicity in 26%. In fact; only 16% of the patients in the maintenance arm received BCG at each of the 7 prescribed courses. Herein, we report on a series of 37 patients with high risk (rapidly recurring grade 2 or 3) Ta, T1 transitional cell carcinoma (TCC) or carcinoma in situ (TIS) of the bladder who received 6 weekly BCG treatments followed by monthly mtce for one year. Patients and Methods: This was a prospective, non-randomized trial of 37 patients with high risk superficial transitional cell carcinoma (TCC) who received one or two 6-week induction courses of intravesical Tice BCG, followed by monthly mtce for 12 months. Entry criteria were identical to those of SWOG 8507. The mean follow-up interval was 40.7 months. Results: Twenty eight of thirty-seven patients (75.7%) remained free of disease recurrence at a median of 40.7 (range 13-101) months. Only one patient progressed to muscle invasive disease. Only 1 of 37 (2.7%) patient experienced grade 3/4 toxicity. Conclusion: In this single institution, monthly maintenance protocol, freedom from recurrence was significant with dramatically less grade 3 or 4 toxicity than reported in SWOG 8507.
Sujet(s)
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Hypercholestérolémie/traitement médicamenteux , Transplantation rénale/physiologie , Lipides/sang , Complications postopératoires , Pyridines/usage thérapeutique , Apolipoprotéines/sang , Cholestérol/sang , Cholestérol HDL/sang , Cholestérol LDL/sang , Ciclosporine/usage thérapeutique , Association de médicaments , Femelle , Humains , Immunosuppresseurs/usage thérapeutique , Mâle , Adulte d'âge moyen , Triglycéride/sangRÉSUMÉ
BACKGROUND: Haemodialysis patients exhibit an excessive burden of atherothrombotic disease, which is not explained adequately by traditional risk factors. Hyperhomocyst(e)inaemia, a consistent finding in uraemic patients, is now widely recognized as an independent risk factor for vascular disease. The aim of this study was to examine the hypothesis that hyperhomocyst(e)inaemia is associated with cardiovascular complications in dialysed patients. METHODS: In a cohort of 63 stable chronic haemodialysis patients, we examined the causal relationship between hyperhomocyst(e)inaemia and vascular endothelial and haemostatic function. All their markers were determined before and after an 8-week course of a 10 mg per day oral folate supplementation, a manoeuvre known to decrease hyperhomocyst(e)inaemia in uraemic patients. RESULTS: History of at least one cardiovascular atherothrombotic event was present in 47.6% of the haemodialysed patients, and radiographic evidence of vascular calcifications in 70%. Hyperhomocyst(e)inaemia was found in all patients, averaging 3.5-fold the upper limit of normal values (P<0.001), despite the lack of clinical and biological evidence of malnutrition. Fibrinogen, von Willebrand factor and plasminogen activator inhibitor type 1, but not endothelin 1, were significantly higher in haemodialysis patients than in controls. After adjustment for all variables, past history of cardiovascular events was independently associated with higher levels of homocyst(e)inaemia only (odds ratio (OR) 1.06; 95% confidence interval (CI) 1.01-1.12; P<0.026). The presence of aortic calcifications was independently and significantly associated with age (OR 1.37; 95% CI 1.07-1.75; P<0.025), homocyst(e)inaemia (OR 1.14; 95% CI 1.02-1.27; P<0.05) and fibrinogen concentration only (OR 9.74; 95% CI 1.25-75.2; P<0.05). None of the endothelial haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term folate supplementation decreased plasma homocyst(e)ine levels significantly without achieving normal values. No significant change of endothelial-haemostatic markers was observed, however, despite the drop in plasma homocyst(e)ine. CONCLUSIONS: Hyperhomocyst(e)inaemia is associated with increased cardiovascular risk in haemodialysis patients. Folate supplementation was partially effective in lowering hyperhomocyst(e)inaemia, but its usefulness in terms of reduction in cardiovascular morbidity and mortality remains to be determined in prospective trials.
Sujet(s)
Maladies cardiovasculaires/épidémiologie , Endothélium vasculaire/physiopathologie , Dialyse rénale , Sujet âgé , Marqueurs biologiques , Maladies cardiovasculaires/étiologie , Études de cohortes , Femelle , Acide folique/usage thérapeutique , Antianémiques/usage thérapeutique , Hémostase , Homocystéine/sang , Homocystine/sang , Humains , Mâle , Adulte d'âge moyen , Morbidité , État nutritionnel , Facteurs de risque , Facteurs tempsRÉSUMÉ
INTRODUCTION: The importance of non-insulin-dependent diabetes mellitus (type II diabetes) as a leading cause of end-stage renal disease is now widely recognized. The purpose of this study was to assess life-prognosis and its predictors in a cohort of patients newly entering dialysis. MATERIAL AND METHODS: Eighty-four consecutive type II diabetes patients (40% of all patients) starting dialysis between 01/01/95 and 31/12/96 were studied retrospectively, focusing on clinical data at inception and life-prognosis after a mean follow-up of 211 days. Patients were divided into three groups, according to onset of renal failure: acute 11% (9/84), chronic 61% (51/84) and acutely aggravated chronic renal failure 28% (25/84). RESULTS: Patients (mean age 67 years) had long-standing diabetes (mean duration approximately 15 years), heavy proteinuria (approximately 3 g/24h) and diabetic retinopathy (67%). The average creatinine clearance (Cockcroft's formula) was 13 ml/min. Cardiovascular diseases were highly prevalent at the start of dialysis: history of myocardial infarction (26%), angina (36%) and acute left ventricular dysfunction (67%). More than 80% of the patients underwent the first session dialysis under emergency conditions, a situation in part related to late referral to the nephrology division (63% for chronic patients). A great majority of the patients were overhydrated when starting dialysis, as evidenced by the average weight loss of 6 kg, during the first month of dialysis, required to reach dry weight. Nearly 64% of the patients presented high blood pressure (> 140/90 mmHg) when starting dialysis despite antihypertensive therapy (mean: 2.3 drugs). The outcome of this type II diabetes population was dramatic: 32% (27/84) died after a mean follow-up of 211 days, mostly from cardiovascular diseases. The rate of recovery of renal function was low in both the acute and the acutely aggravated renal failure group (30% and 24%, respectively). Of note, iatrogenic nephrotoxic agents accounted for renal function impairment in nearly 30% of patients. CONCLUSION: Our observational study illustrates the high burden of cardiovascular diseases contrasting with sub-optimal cardiovascular therapeutic interventions in type II diabetes patients entering dialysis. Factors aggravating renal failure were mainly iatrogenic, and therefore largely avoidable. Late referral generally implied a poor clinical condition at the start of dialysis.
Sujet(s)
Atteinte rénale aigüe/thérapie , Diabète de type 2/thérapie , Néphropathies diabétiques/thérapie , Défaillance rénale chronique/thérapie , Dialyse rénale , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/mortalité , Sujet âgé , Pression sanguine , Maladies cardiovasculaires/épidémiologie , Diabète de type 2/mortalité , Angiopathies diabétiques/épidémiologie , Néphropathies diabétiques/mortalité , Femelle , Études de suivi , Humains , Défaillance rénale chronique/étiologie , Défaillance rénale chronique/mortalité , Mâle , Adulte d'âge moyen , Prévalence , Pronostic , Dialyse rénale/mortalité , Études rétrospectives , Analyse de survie , Facteurs temps , Résultat thérapeutiqueSujet(s)
Athlètes , Comportement compétitif , Gymnastique , Systèmes politiques , Athlètes/enseignement et éducation , Athlètes/histoire , Athlètes/législation et jurisprudence , Athlètes/psychologie , Communisme/économie , Communisme/histoire , Comparaison interculturelle , Danemark/ethnologie , Gymnastique/économie , Gymnastique/enseignement et éducation , Gymnastique/histoire , Gymnastique/physiologie , Gymnastique/psychologie , Histoire du 20ème siècle , Humains , Systèmes politiques/histoire , Groupes de population/enseignement et éducation , Groupes de population/ethnologie , Groupes de population/histoire , Groupes de population/législation et jurisprudence , Groupes de population/psychologie , Sports/économie , Sports/enseignement et éducation , Sports/histoire , Sports/législation et jurisprudence , Sports/physiologie , Sports/psychologie , URSS/ethnologieRÉSUMÉ
In a steady-state cross-over study in 18 healthy volunteers, the relative bioavailability of beta-escin (CAS 11072-93-8) after oral administration of a new immediate release enteric-coated test formulation containing aesculus extract was evaluated in comparison with a prolonged-release reference preparation. The subject received the test and the reference preparation in randomised sequence for 7 days each with no washout period in between. The daily dose was 50 mg escin b.i.d. Blood samples for pharmacokinetic profiling were taken on the 7th treatment day of each period over a full 24-h cycle of two successive dosing intervals. For the determination of beta-escin serum concentrations, a highly specific radioimmunoassay (RIA) was used. Generally, escin serum concentrations were lower during the second dosing interval (night) than during the first interval, probably indicating a drug by food interaction. (The morning dose was given after overnight fasting whereas the evening dose was given between meals). Test and reference demonstrated bioequivalence with regard to the extent of absorption; for the AUC (0-24 h p.a.), the 90% confidence interval ranged from 84% to 114% (point estimate: 98%). The differences observed for rate parameters can be disregarded due to the generally slow elimination and the wide therapeutic concentration range of escin.
Sujet(s)
Anti-inflammatoires non stéroïdiens/pharmacocinétique , Aescine/pharmacocinétique , Plantes médicinales/composition chimique , Administration par voie orale , Adolescent , Adulte , Anti-inflammatoires non stéroïdiens/administration et posologie , Aire sous la courbe , Biodisponibilité , Études croisées , Aescine/administration et posologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Extraits de plantes/administration et posologie , Extraits de plantes/pharmacocinétique , Dosage radioimmunologique , Comprimés entérosolublesRÉSUMÉ
OBJECTIVES: We sought to describe the effect of a Helicobacter pylori eradication strategy on health care costs among a cohort of health maintenance organization (HMO) members with peptic ulcer disease (PUD). METHODS: Patients were identified from an outpatient diagnosis database and verified at chart review to have new-onset PUD by upper endoscopy or upper gastrointestinal radiographic series. Health plan registration and accounting databases were used to track costs over 12 months after initial diagnosis. Costs were analyzed separately for an initial 2-month interval and a 10-month follow-up period. Inpatient and pharmacy costs are those directly attributable to PUD (either a PUD-related discharge diagnosis or an antiulcer medication prescription). Outpatient costs are total costs. All cost differences were adjusted for age and gender. RESULTS: Twenty-seven of 93 patients meeting selection criteria received H. pylori treatment. During the 2-month treatment window, adjusted PUD-related inpatient costs were higher for the H. pylori treated group (difference, $234.00/person), whereas total outpatient costs and PUD-related pharmacy costs were similar. During the 10-month follow-up period, PUD-related inpatient and pharmacy adjusted costs were similar, but adjusted outpatient costs in the H. pylori treated group were lower than in the untreated group (difference, $508.00/person). Total adjusted follow-up period costs were $555.00/person less in the H. pylori treated group (p = 0.05). Total 12-month costs in the H. pylori treated group were $285.00/per person less than in untreated patients, (p > 0.2); 30% of H. pylori treated patients were still receiving antisecretory therapy 1 yr after diagnosis, compared to 41.9% of untreated patients. CONCLUSIONS: H. pylori treatment is associated with a decreased cost of follow-up care for patients with PUD, primarily due to decreased outpatient utilization.
Sujet(s)
Health Maintenance Organizations (USA)/économie , Infections à Helicobacter/économie , Helicobacter pylori , Ulcère peptique/économie , Soins ambulatoires/économie , Coûts et analyse des coûts , Coûts des médicaments , Femelle , Infections à Helicobacter/complications , Infections à Helicobacter/traitement médicamenteux , Humains , Mâle , Adulte d'âge moyen , Ulcère peptique/traitement médicamenteux , Ulcère peptique/microbiologieRÉSUMÉ
OBJECTIVE: We compared quality of life, utilization, and costs for women undergoing elective abdominal, laparoscopically assisted vaginal, or vaginal hysterectomy within a managed-care organization. STUDY DESIGN: A prospective study of 287 women who underwent an elective hysterectomy was performed. RESULTS: Patients undergoing a vaginal hysterectomy reported returning to normal activity levels sooner and had more favorable quality-of-life scores than did those undergoing laparoscopically assisted vaginal hysterectomy or abdominal hysterectomy. Laparoscopically assisted vaginal hysterectomy was often nearly as favorable as vaginal hysterectomy, particularly at 28 days after the operation, whereas the abdominal hysterectomy group consistently reported the poorest postoperative quality-of-life scores. No significant differences were noted in utilization or costs in the 60-day preoperative period, whereas hospitalization and postoperative costs were highest among the abdominal hysterectomy group and lowest for those undergoing a vaginal hysterectomy. CONCLUSIONS: Vaginal hysterectomy resulted in better quality-of-life outcomes and lower utilization and costs compared with laparoscopically assisted vaginal or abdominal hysterectomy.
Sujet(s)
Hystérectomie vaginale/statistiques et données numériques , Hystérectomie/statistiques et données numériques , Laparoscopie/statistiques et données numériques , Programmes de gestion intégrée des soins de santé/économie , Qualité de vie , Service de santé pour les femmes/statistiques et données numériques , Adulte , Analyse coût-bénéfice , Niveau d'instruction , Endométriose/économie , Endométriose/chirurgie , Femelle , Fibrome/économie , Fibrome/chirurgie , Coûts des soins de santé , Humains , Hystérectomie/économie , Hystérectomie vaginale/économie , Revenu , Entretiens comme sujet , Laparoscopie/économie , Laparoscopie/méthodes , Durée du séjour , Situation de famille , Adulte d'âge moyen , Prolapsus , Études prospectives , Résultat thérapeutique , Maladies de l'utérus/économie , Maladies de l'utérus/chirurgie , Tumeurs de l'utérus/économie , Tumeurs de l'utérus/chirurgie , Service de santé pour les femmes/économieSujet(s)
Homocystéine/métabolisme , Défaillance rénale chronique/métabolisme , Homocystéine/sang , Homocystéine/toxicité , Humains , Rein/métabolisme , Défaillance rénale chronique/complications , Methylenetetrahydrofolate reductase (NADPH2) , Oxidoreductases acting on CH-NH group donors/physiologieRÉSUMÉ
This study evaluated the economic impact of patient-focused pharmacist intervention in the community retail setting in patients with hypertension, diabetes, asthma, and/or hypercholesterolemia. Specially trained pharmacists intervened by providing targeted patient education, performing systematic patient monitoring, offering feedback and behavior modification, and communicating regularly with patients' physicians to enable early intervention for drug-related problems. We evaluated prescription drug costs and total medical costs by comparing claims data from 188 patients enrolled in the program at three intervention pharmacies with data from 401 control patients at five nonparticipating pharmacies from the same retail chain. For all disease states, the average cost per prescription was significantly higher in the group receiving intervention than in the control group. Differences in total monthly prescription costs were significant only for patients with asthma, with higher monthly costs in the group receiving intervention. Substantial savings were demonstrated across all cost analyses for total monthly medical costs. Savings ranged from a conservative estimate of $143.95 per patient per month to $293.39 per patient per month when accounting for the possible influence of age, comorbid conditions, and disease severity. Our data indicate that pharmacist intervention in this community pharmacy-based disease management model substantially reduced monthly health care costs in patients with hypertension, hypercholesterolemia, diabetes, and asthma.
Sujet(s)
Services des pharmacies communautaires/économie , Services des pharmacies communautaires/organisation et administration , Pharmacoéconomie , Frais d'ordonnance , Sujet âgé , Femelle , Coûts des soins de santé , Humains , Mâle , Adulte d'âge moyen , Éducation du patient comme sujetRÉSUMÉ
Hemodialysis can achieve loss of body water, variable in the different water compartments, and that depends on the dry weight and the composition of the dialysate. We have studied echocardio-Doppler findings in 26 end stage renal disease patients (from 26 to 84 years), in whom 25 have hypertension, in sinusal rythm and ejection fraction above 55%. When they achieved a 3.52% decrease in body weight, without modification of heart rate and decrease in median arterial pression, these patients exhibited decrease in auricular (p = 0.001) and ventricular diameter both in systole and diastole (p = 0.001), in maximum velocity of E wave (p = 0.001) and E/A ratio. There was no significant reduction of maximum velocity of A wave, but 4 differents patterns of E/A ratio were demonstrated. The main determinant factor of these patterns was found to be the age of the patient.
Sujet(s)
Échocardiographie-doppler , Défaillance rénale chronique/imagerie diagnostique , Défaillance rénale chronique/thérapie , Dialyse rénale , Fonction ventriculaire gauche , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Vieillissement , Pression sanguine , Femelle , Ventricules cardiaques/imagerie diagnostique , Ventricules cardiaques/physiopathologie , Hémodynamique , Humains , Défaillance rénale chronique/physiopathologie , Mâle , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Little is known about the economic impact of the acid-related disorders (ARDs), which include dyspepsia, gastritis, gastroesophageal reflux disease (GERD), and peptic ulcer disease (PUD), in managed care patient populations. OBJECTIVES: To describe the prevalence of medically attended ARDs, and their direct medical costs from the perspective of a large health maintenance organization (HMO). METHODS: A total of 1,550 ARDs subjects (age > or = 18 years), were randomly sampled from outpatient diagnosis and pharmacy databases of the Kaiser Permanente Medical Care Program of Northern California and verified by chart review. Five age- and gender-matched controls were identified per subject. One-year prevalence, excess annual costs, and initial 6-month costs for incident cases were estimated using the HMO cost accounting system. RESULTS: Total ARDs prevalence (5.8%) increases with advancing age. GERD is the most common ARD (2.9% overall prevalence). Annual per person attributable costs were $1,183, $471, and $431 respectively for PUD, GERD, and gastritis/dyspepsia. Excess inpatient costs for PUD explain its higher costs. Outpatient costs were somewhat higher for GERD ($279) than for PUD or gastritis/dyspepsia. Pharmacy costs were relatively low for each condition, in part because many patients were treated with generic cimetidine. Total annual HMO expenditures for ARDs were $59.4 million, with 40.6%, 36.8%, and 22.6% respectively for GERD, PUD, and gastritis/dyspepsia. CONCLUSIONS: Acid-related disorders, particularly GERD and PUD, contribute substantially to the direct costs of medical care in this managed care population.
Sujet(s)
Dyspepsie/économie , Gastrite/économie , Reflux gastro-oesophagien/économie , Coûts des soins de santé , Health Maintenance Organizations (USA)/économie , Ulcère peptique/économie , Adulte , Sujet âgé , Californie , Femelle , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.
Sujet(s)
Héparine/effets indésirables , Thrombopénie/induit chimiquement , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Fractures osseuses/complications , Fractures osseuses/thérapie , Héparine/administration et posologie , Prothèse de hanche , Humains , Mâle , Adulte d'âge moyen , Agrégation plaquettaire , Thrombopénie/complications , Thromboembolie/sang , Thromboembolie/induit chimiquement , Thromboembolie/traitement médicamenteux , Activateur tissulaire du plasminogène/usage thérapeutiqueRÉSUMÉ
PIP: Moldova, like other newly independent states (NIS), is in urgent need of health education materials that address reproductive health and family planning concerns in the local language. The lack of such information has been cited as a major factor in the alarming rise in sexually transmitted disease (STD) transmission in Eastern Europe. A recent family health education mission to Moldova developed a strategy for a successful campaign. Health care professionals will be the first target group. A series of seminars and workshops will be directed at sex education teachers, hospital personnel, mass media representatives, and other relevant groups. In addition, four weekly television programs on breast feeding, infertility, STDs, and reproductive health are scheduled and simple informational brochures will be distributed. The plan will be linked to Healthy Lifestyle initiatives in the state.^ieng